期刊
NPJ VACCINES
卷 6, 期 1, 页码 -出版社
NATURE RESEARCH
DOI: 10.1038/s41541-021-00289-5
关键词
-
资金
- Pasteur Foundation Asia
- Centers for Disease Control and Prevention [IP001064-02]
- General Research Fund of the University Grants Committee of Hong Kong [17113718]
- University of Hong Kong [201810159004]
The study indicates that using vaccines with higher antigen content or adjuvants can enhance the efficacy of standard-dose seasonal influenza vaccines in older adults. Enhanced vaccines showed better induction of specific antibodies and cellular responses compared to standard-dose vaccines, especially in enhancing cellular cytotoxicity and T cell responses.
The vaccine efficacy of standard-dose seasonal inactivated influenza vaccines (S-IIV) can be improved by the use of vaccines with higher antigen content or adjuvants. We conducted a randomized controlled trial in older adults to compare cellular and antibody responses of S-IIV versus enhanced vaccines (eIIV): MF59-adjuvanted (A-eIIV), high-dose (H-eIIV), and recombinant-hemagglutinin (HA) (R-eIIV). All vaccines induced comparable H3-HA-specific IgG and elevated antibody-dependent cellular cytotoxicity (ADCC) activity at day 30 post vaccination. H3-HA-specific ADCC responses were greatest following H-eIIV. Only A-eIIV increased H3-HA-IgG avidity, HA-stalk IgG and ADCC activity. eIIVs also increased polyfunctional CD4+ and CD8+ T cell responses, while cellular immune responses were skewed toward single-cytokine-producing T cells among S-IIV subjects. Our study provides further immunological evidence for the preferential use of eIIVs in older adults as each vaccine platform had an advantage over the standard-dose vaccine in terms of NK cell activation, HA-stalk antibodies, and T cell responses.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据